Simbrunner, Benedikt
Hofer, Benedikt S.
Schwabl, Philipp
Zinober, Kerstin
Petrenko, Oleksandr
Fuchs, Claudia
Semmler, Georg
Marculescu, Rodrig
Mandorfer, Mattias
Datz, Christian
Trauner, Michael
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
https://doi.org/10.1007/s12072-020-10112-3
Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
https://doi.org/10.1007/s12072-023-10496-y
FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
https://doi.org/10.1007/s12072-023-10636-4
Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
https://doi.org/10.1007/s12072-023-10577-y
Funding for this research was provided by:
Gilead Sciences (International Research Scholar)
Medical University of Vienna
Article History
Received: 20 July 2023
Accepted: 22 December 2023
First Online: 8 February 2024
Declarations
:
: BeSi has received travel support from AbbVie and Gilead and was supported by an International Research scholar by Gilead Sciences awarded to TR. PS received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk and Phenex Pharmaceuticals. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, Collective Acumen, and W. L. Gore & Associates and received travel support from AbbVie, Bristol-Myers Squibb, and Gilead. CD is part of the scientific advisory board of SPAR Österreich AG. MT served as a speaker and/or consultant and/or advisory board member for Albireo, BiomX, Falk, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, and Shire, and received travel support from AbbVie, Falk, Gilead, and Intercept, as well as grants/research support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and UltraGenyx. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid. TR received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Abbvie, Boehringer-Ingelheim, Gilead and Roche. BH, OP, CF, GS, RM and KZi declare no conflict of interest.
: The study was conducted in accordance with the principles of the Declaration of Helsinki and its amendments. Patients gave written informed consent for hepatic vein catheterization, colonoscopy, and enrolment in the VICIS study (EK1262/2017). Regarding control liver samples, patients gave written informed consent for liver resections and participation in the LIVERMATRIX study (EK 2318/2019). Regarding control ileum samples, individuals gave written informed consent for colonoscopy and participation in the SAKKOPI study (415-E/1262/2-2010). The studies were approved by the local ethics committees of Salzburg and the Medical University of Vienna, respectively.